Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report

Patients treated with immune checkpoint inhibitors (ICIS) are prone to immune related adverse events (irAEs), making it important to pay attention to these adverse events. Herein, we report a case of onychopathy after treatment of extensive small cell lung cancer (ES-SCLC) with durvalumab; this is t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Cuifen, Wang, Ke, Zhang, Hong, Liu, Jingjing, Zheng, Chuangjie, Tao, Jiahao, Lin, Lizhu, Zhai, Linzhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492564/
https://www.ncbi.nlm.nih.gov/pubmed/37694194
http://dx.doi.org/10.2147/CCID.S415119
_version_ 1785104283923906560
author Zhang, Cuifen
Wang, Ke
Zhang, Hong
Liu, Jingjing
Zheng, Chuangjie
Tao, Jiahao
Lin, Lizhu
Zhai, Linzhu
author_facet Zhang, Cuifen
Wang, Ke
Zhang, Hong
Liu, Jingjing
Zheng, Chuangjie
Tao, Jiahao
Lin, Lizhu
Zhai, Linzhu
author_sort Zhang, Cuifen
collection PubMed
description Patients treated with immune checkpoint inhibitors (ICIS) are prone to immune related adverse events (irAEs), making it important to pay attention to these adverse events. Herein, we report a case of onychopathy after treatment of extensive small cell lung cancer (ES-SCLC) with durvalumab; this is the first report of onychopathy caused by durvalumab in a patient with lung cancer. The change in the patient’s nails mainly manifested in the form of pigmentation and the thickening of the nails. Antifungal ointment was ineffective, and these changes were unrelated to malnutrition or any other factors. In addition, this case shows that onychopathy may occur within 2 years after treatment, indicating that these patients need long-term follow-up.
format Online
Article
Text
id pubmed-10492564
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104925642023-09-10 Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report Zhang, Cuifen Wang, Ke Zhang, Hong Liu, Jingjing Zheng, Chuangjie Tao, Jiahao Lin, Lizhu Zhai, Linzhu Clin Cosmet Investig Dermatol Case Report Patients treated with immune checkpoint inhibitors (ICIS) are prone to immune related adverse events (irAEs), making it important to pay attention to these adverse events. Herein, we report a case of onychopathy after treatment of extensive small cell lung cancer (ES-SCLC) with durvalumab; this is the first report of onychopathy caused by durvalumab in a patient with lung cancer. The change in the patient’s nails mainly manifested in the form of pigmentation and the thickening of the nails. Antifungal ointment was ineffective, and these changes were unrelated to malnutrition or any other factors. In addition, this case shows that onychopathy may occur within 2 years after treatment, indicating that these patients need long-term follow-up. Dove 2023-09-05 /pmc/articles/PMC10492564/ /pubmed/37694194 http://dx.doi.org/10.2147/CCID.S415119 Text en © 2023 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Zhang, Cuifen
Wang, Ke
Zhang, Hong
Liu, Jingjing
Zheng, Chuangjie
Tao, Jiahao
Lin, Lizhu
Zhai, Linzhu
Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report
title Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report
title_full Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report
title_fullStr Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report
title_full_unstemmed Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report
title_short Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report
title_sort onychopathy following durvalumab treatment for extensive-stage small-cell lung cancer: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492564/
https://www.ncbi.nlm.nih.gov/pubmed/37694194
http://dx.doi.org/10.2147/CCID.S415119
work_keys_str_mv AT zhangcuifen onychopathyfollowingdurvalumabtreatmentforextensivestagesmallcelllungcanceracasereport
AT wangke onychopathyfollowingdurvalumabtreatmentforextensivestagesmallcelllungcanceracasereport
AT zhanghong onychopathyfollowingdurvalumabtreatmentforextensivestagesmallcelllungcanceracasereport
AT liujingjing onychopathyfollowingdurvalumabtreatmentforextensivestagesmallcelllungcanceracasereport
AT zhengchuangjie onychopathyfollowingdurvalumabtreatmentforextensivestagesmallcelllungcanceracasereport
AT taojiahao onychopathyfollowingdurvalumabtreatmentforextensivestagesmallcelllungcanceracasereport
AT linlizhu onychopathyfollowingdurvalumabtreatmentforextensivestagesmallcelllungcanceracasereport
AT zhailinzhu onychopathyfollowingdurvalumabtreatmentforextensivestagesmallcelllungcanceracasereport

Ejemplares similares